Reference is made to the notice of the extraordinary general meeting in NorDiag ASA to be held on Monday 16 April 2012.
 
The company has established an underwriting syndicate to guarantee subscriptions for NOK 8,140,000 in a rights issue to be decided by the extraordinary general meeting. The Board of Directors of NorDiag will publish terms and conditions prior to the general meeting.
 
For further information, please contact:
CEO Mårten Wigstøl Phone: +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNAfrom difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 29.15 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.

Read the notice in Norwegian here.